Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 1045-4403
ISSN Online: 2162-6502
Indexed in
The Cellular and Clinical Parameters of Anabolic Therapy for Osteoporosis
ABSTRAKT
A new era in the management of osteoporosis began with the recent approval of parathyroid hormone (PTH) for the treatment of postmenopausal osteoporosis. This peptide holds promise as the first in a series of anabolic growth factors that promote bone formation, enhance mineralization, and stimulate periosteal growth, yet exert relatively limited effects on bone resorption. Daily intermittent PTH treatment for postmenopausal women results in a dramatic increase in bone mineral density (BMD) (i.e., 10–15% improvement in spine BMD) and a significant decline (i.e., a risk reduction of nearly 2/3) in the occurrence of fragility fractures. The mechanism of PTH’s anabolic action on the skeleton is complex and involves multiple pathways linked to common signaling peptides that affect gene transcription in osteoblasts. One fascinating aspect of PTH, both at the clinical and molecular level, is the relationship between the frequency of PTH treatment and the bone response. Depending on the type of PTH exposure, there can be an anabolic or catabolic skeletal phenotype that can then be recapitulated by certain in vivo and in vitro model systems. Transcriptional events following ligand binding to the PTH/PTHrP1 receptor have been studied, with particular interest in target genes such as IGF-I that can regulate both bone formation and resorption. Novel in vivo strategies, including temporal and conditional mutagenesis, will almost certainly lead to newer therapeutic paradigms for the treatment of postmenopausal osteoporosis.
-
Phelps E., Bezouglaia O., Tetradis S., Nervina J. M., Parathyroid Hormone Induces Receptor Activity Modifying Protein-3 (RAMP3) Expression Primarily Via 3′,5′-Cyclic Adenosine Monophosphate Signaling in Osteoblasts, Calcified Tissue International, 77, 2, 2005. Crossref
-
Elis Sebastien, Courtland Hayden-William, Wu Yingjie, Fritton J Christopher, Sun Hui, Rosen Clifford J, Yakar Shoshana, Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact, Journal of Bone and Mineral Research, 25, 9, 2010. Crossref
-
Jódar-Gimeno Esteban, Full length parathyroid hormone (1?84) in the treatment of osteoporosis in postmenopausal women, Clinical Interventions in Aging, 2, 1, 2007. Crossref
-
Lyritis George P., Georgoulas Thomas, Zafeiris Christos P, Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis, Annals of the New York Academy of Sciences, 1205, 1, 2010. Crossref
-
Lian Jane B., Stein Gary S., Javed Amjad, van Wijnen Andre J., Stein Janet L., Montecino Martin, Hassan Mohammad Q., Gaur Tripti, Lengner Christopher J., Young Daniel W., Networks and hubs for the transcriptional control of osteoblastogenesis, Reviews in Endocrine and Metabolic Disorders, 7, 1-2, 2006. Crossref
-
Segovia-Silvestre T., Neutzsky-Wulff A. V., Sorensen M. G., Christiansen C., Bollerslev J., Karsdal M. A., Henriksen K., Advances in osteoclast biology resulting from the study of osteopetrotic mutations, Human Genetics, 124, 6, 2009. Crossref
-
Gazzerro Elisabetta, Canalis Ernesto, Skeletal actions of insulin-like growth factors, Expert Review of Endocrinology & Metabolism, 1, 1, 2006. Crossref
-
Centrella Michael, Christakos Sylvia, McCarthy Thomas L., Skeletal hormones and the C/EBP and Runx transcription factors: interactions that integrate and redefine gene expression, Gene, 342, 1, 2004. Crossref
-
McCarthy Thomas L., Kallen Caleb B., Centrella Michael, β-Catenin independent cross-control between the estradiol and Wnt pathways in osteoblasts, Gene, 479, 1-2, 2011. Crossref
-
Girotra Monica, Cosman Felicia, Bilezikian John P., Treatment of Male Osteoporosis with Parathyroid Hormone, in Osteoporosis in Men, 2010. Crossref
-
LIAN JANE B., STEIN GARY S., The Cells of Bone, in Dynamics of Bone and Cartilage Metabolism, 2006. Crossref
-
Zhou Fangfang, Huang Huizhe, Zhang Long, Bisindoylmaleimide I enhances osteogenic differentiation, Protein & Cell, 3, 4, 2012. Crossref
-
Capriani Cristiana, Irani Dinaz, Bilezikian John P, Safety of osteoanabolic therapy: A decade of experience, Journal of Bone and Mineral Research, 27, 12, 2012. Crossref
-
Aubin Jane E., Mesenchymal Stem Cells and Osteoblast Differentiation, in Principles of Bone Biology, 2008. Crossref
-
Liu Yan-Qiu, Han Xiao-Fei, Liu Tiegang, Cheng Meng-Chun, Xiao Hong-Bin, A cell-based model of bone remodeling for identifying activity of icarrin in the treatment of osteoporosis, Biotechnology Letters, 37, 1, 2015. Crossref
-
Schultz Thomas C, Valenzano Jonathan P, Verzella Jessica L, Umland Elena M, Odanacatib: An Emerging Novel Treatment Alternative for Postmenopausal Osteoporosis, Women's Health, 11, 6, 2015. Crossref
-
Echeverri A.F., Ospina F.E., Cañas C.A., Agualimpia A., Suso J.P., Tobón G.J., Bonilla-Abadía F., Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients, British Journal of Dermatology, 175, 5, 2016. Crossref
-
Htet T. D., Eisman J. A., Elder G. J., Center J. R., Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide, Osteoporosis International, 29, 2, 2018. Crossref
-
Hsu Jeffrey J., Lu Jinxiu, Umar Soban, Lee Jason T., Kulkarni Rajan P., Ding Yichen, Chang Chih-Chiang, Hsiai Tzung K., Hokugo Akishige, Gkouveris Ioannis, Tetradis Sotirios, Nishimura Ichiro, Demer Linda L., Tintut Yin, Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice, American Journal of Physiology-Heart and Circulatory Physiology, 314, 6, 2018. Crossref
-
Teplyuk Nadiya M., Zhang Ying, Lou Yang, Hawse John R., Hassan Mohammad Q., Teplyuk Viktor I., Pratap Jitesh, Galindo Mario, Stein Janet L., Stein Gary S., Lian Jane B., van Wijnen Andre J., The Osteogenic Transcription Factor Runx2 Controls Genes Involved in Sterol/Steroid Metabolism, Including Cyp11a1 in Osteoblasts, Molecular Endocrinology, 23, 6, 2009. Crossref
-
Hock J. M., Basic Aspects of PTH in Skeletal Health, in Osteoporosis, 2010. Crossref
-
Clemmons David R., Insulin-Like Growth Factor-1 and Its Binding Proteins, in Endocrinology, 2010. Crossref
-
Yamaguchi Masayuki, Ogata Naoshi, Shinoda Yusuke, Akune Toru, Kamekura Satoru, Terauchi Yasuo, Kadowaki Takashi, Hoshi Kazuto, Chung Ung-Il, Nakamura Kozo, Kawaguchi Hiroshi, Insulin Receptor Substrate-1 Is Required for Bone Anabolic Function of Parathyroid Hormone in Mice, Endocrinology, 146, 6, 2005. Crossref
-
McCarthy Thomas L., Clough Mary E., Gundberg Caren M., Centrella Michael, Expression of an estrogen receptor agonist in differentiating osteoblast cultures, Proceedings of the National Academy of Sciences, 105, 19, 2008. Crossref
-
Teplyuk Nadiya M., Galindo Mario, Teplyuk Viktor I., Pratap Jitesh, Young Daniel W., Lapointe David, Javed Amjad, Stein Janet L., Lian Jane B., Stein Gary S., van Wijnen Andre J., Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast Progenitors, Journal of Biological Chemistry, 283, 41, 2008. Crossref